COVID-19 Vaccine: Experts discuss promise, prevention in Twitter chat amid race for a working vaccine

I’m confident we’ll get a COVID-19 vaccine, just not sure which candidate(s) will make it into people’s arms, one expert said.

Reuters July 23, 2020 09:46:49 IST
COVID-19 Vaccine: Experts discuss promise, prevention in Twitter chat amid race for a working vaccine

As the global race for a COVID-19 vaccine heats up, Reuters invited a group of healthcare experts to answer questions as part of a Twitter chat series.

Digital special projects editor Lauren Young asked participants which vaccine candidates show the most promise, and what to expect in terms of prevention, safety and vaccine roll out.

Below are the edited answers.

"The early trial results of several vaccines, that is the results of Phase 1 and/or Phase 2 trials, have been very promising. We should definitely ‘believe’ these results, while acknowledging that they do not prove the vaccine is effective.

These early phase trials address safety and whether the vaccine elicits a good immune response. The good news is that we have several vaccines that have or are moving forward into Phase 3 trials, the phase needed to prove it ‘works’ for licensing."

— Aubree Gordon, associate professor of epidemiology at University of Michigan School of Public Health

“Hard to draw any firm conclusions from Phase 1 and 2 data and press releases. AstraZeneca/Oxford vaccine has animal data. I’m confident we’ll get a COVID-19 vaccine, just not sure which candidate(s) will make it into people’s arms.”

— Amesh Adalja, senior scholar at Johns Hopkins University Center for Health Security

“We can have faith in several potential vaccines because they’re built off other successful efforts. Oxford/AstraZeneca, some (National Institute of Health) and one in China are all promising. But here’s what makes me most worried: global competition instead of collaboration is harming. In this pandemic, we need to quickly realize there are better ways of doing this.”

— Matthew Kavanagh, assistant professor of global health and visiting professor of Law at Georgetown University; director of global health policy & politics initiative at O’Neill Institute

“The “mad rush” to be first to market should NOT compromise the science in any way. We have very stringent scientific principles for scientific studies and these should not be compromised ... Ethics is of the utmost importance in any scientific study.”

— Dr. Krutika Kuppalli, emerging leader in biosecurity fellow at Johns Hopkins University Center for Health Security

“We have vaccine candidates coming to Phase 3 trials within seven months of knowing the genetic sequence of the virus. This is what can happen when public, academic & private entities come together with a single focus. When united, we can accomplish so much more!”

— Infectious Diseases Society of America

“Things will be confusing come the fall with both COVID-19 and the flu active at the same time. Since we have an effective vaccine for the flu, at least we can get protection against one of them.

— Raed Dweik, chairman of the Respiratory Institute at Cleveland Clinic

Updated Date:

also read

Brazilian state Parana inks deal to test, manufacture Russia's Sputnik V COVID-19 vaccine
World

Brazilian state Parana inks deal to test, manufacture Russia's Sputnik V COVID-19 vaccine

Under the terms of the deal, Russia will reportedly share the results of Phase 1 and 2 testing with the state.

Serum Institute gets DCGI nod to conduct phase 2, 3 human trials of Oxford vaccine in 1,600 healthy volunteers in India
India

Serum Institute gets DCGI nod to conduct phase 2, 3 human trials of Oxford vaccine in 1,600 healthy volunteers in India

Serum Institute has partnered with AstraZeneca to manufacture the vaccine, saying in a statement that it will make a billion doses once cleared by regulatory authorities.

Trump announces sixth vaccine contract for US, for 100 mn doses of Moderna's COVID-19 vaccine
World

Trump announces sixth vaccine contract for US, for 100 mn doses of Moderna's COVID-19 vaccine

As per the contract, the US has secured 100 million doses as soon as the vaccine is approved, and another 500 million not long after.